Latest Media Releases (Page 8) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Radiopharm Theranostics - Completion of Entitlement Offer (ASX:RAD)

On 31 October 2023, Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) announced the details of a non-renounceable entitlement offer (Entitlement Offer) to raise approximately $10 mil...read more

Chimeric Therapeutics - Completion of Entitlement Offer (ASX:CHM)

On 25 October 2023, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of a non-renounceable entitlement offer (Entitlement Offer) to raise approximately $10 million...read more

Immutep receives A$2.6 million French R&D Tax Incentive (ASX:IMM)

SYDNEY, AUSTRALIA – 7 December 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related i...read more

INOVIQ - 2023 AGM CEO Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

Austco Healthcare - Teknocorp acquisition completion (ASX:AHC)

Austco Healthcare Limited (Austco) (ASX:AHC) is pleased to announce the completion of the acquisition of the business and assets of Victorian-based Teknocorp Australia Pty Ltd and its related busine...read more

Chimeric Therapeutics - Positive in vitro data for CHM 1301 CAR NK cells (ASX:CHM)

Positive preclinical data for CHM 1301, a next generation off the shelf CLTX CAR NK cell therapy Up to 300% enhanced cell killing demonstrated compared to first generation NK c...read more

Immutep Announces Site Expansion for INSIGHT-003 Trial (ASX:IMM)

SYDNEY, AUSTRALIA – November 22, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...read more

Radiopharm receives $4.85M R&D tax incentive (ASX:RAD)

Sydney, Australia – 21 November 2023 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and thera...read more

INOVIQ - Bell Potter Healthcare Conference Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

Immutep completes enrolment for TACTI-003 Phase IIb Trial (ASX:IMM)

A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb trial evaluating efti in combination with pembrolizumab ...read more

INOVIQ - ANSEV Meeting Presentations (ASX:IIQ)

Melbourne, Australia, 8 November 2023: INOVIQ Limited (ASX:IIQ) today advises that it will present new data on the effectiveness and utility of its proprietary exosome isolation technology, EXO-NET&...read more

Radiopharm Theranostics - Entitlement Offer Documents (ASX:RAD)

Sydney, Australia – 8 November 2023 – Radiopharm Theranostics (ASX:RAD), a developer of a worldclass platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is...read more

Next Science - Response to ASX Aware Letter (ASX:NXS)

Dear Ms Banh ASX QUERY I refer to your letter dated 3 November 2023 regarding ASX's queries in respect of Next Science Limited (“Next Science” or “Company”), and sp...read more

Immutep - Lead-in phase completed for ph2/3 trial in Breast Cancer (ASX:IMM)

-- No safety or tolerability issues in open-label, safety lead-in phase evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients -- Good safety profile ...read more

Next Science - XPERIENCE study findings released (ASX:NXS)

Study finds Infection Prevention Benefit in Periprosthetic Joint Surgery for XPERIENCE™ ADVANCED SURGICAL IRRIGATION Highlights: Dr. Robert Harris MD has released the finding...read more

Viewing: 106 - 120 of 200 Previous | Next